Wed Mar 05 11:00:54 UTC 2025: ## 18-Year Cancer Remission Achieved Through CAR T-Cell Therapy: A New Milestone
**Bangalore, India (March 6, 2025)** – A significant breakthrough in cancer treatment has been reported, offering new hope for patients battling the disease. Researchers announced in *Nature Medicine* that a patient with neuroblastoma, a type of nerve cell cancer, has remained in remission for 18 years following CAR T-cell therapy, without the need for any further treatment. This is potentially the longest remission achieved using this groundbreaking therapy.
CAR T-cell therapy involves genetically modifying a patient’s immune cells (T cells) to target and destroy cancer cells. The modified T cells, equipped with chimeric antigen receptors (CARs), are more effective at identifying and eliminating cancerous cells that might otherwise evade the body’s natural defenses.
The patient, who participated in a clinical trial between 2004 and 2009, received the therapy as a child. While the trial showed twelve of the eighteen participants succumbed to their neuroblastoma relapse, this individual’s sustained remission highlights the therapy’s potential, particularly given neuroblastoma’s classification as a solid tumor, which has proven more challenging to treat with CAR T-cell therapy.
Researchers emphasize that significant advancements have been made in CAR T-cell therapy since the initial trial, including the development of “armored CARs” that enhance the therapy’s effectiveness. The long-term remission of this patient underscores the ongoing promise of CAR T-cell therapy in the fight against cancer.
First Piper 